2016 Hematological Malignancies

Nivolumab in r&r HL Best response

25 0

SD(13%)

PR 65%

CR (22%)

–25

–50

–75

–100

Patients (n = 23)

Percent Change in Tumor Burden

On treatment, ongoing response Off treatment without disease progression a

Progressive disease, following response or stable disease

Ansell et al; ASH 2015